Breakthrough in Prostate Cancer Treatment: New Immunotherapy Shows Promise

A new treatment that leverages the body's immune system to combat prostate cancer has shown significant promise in early clinical trials. The innovative therapy, known as pasritamig, has demonstrated the ability to shrink tumors and achieve a median progression-free survival of nearly eight months in patients with advanced prostate cancer. This breakthrough treatment works by bridging T cells to prostate cancer cells, allowing the immune system to recognize and attack the tumor. Researchers were surprised to find that a moderate dose of pasritamig, administered via IV infusion every six weeks, was the most effective approach.

Key Takeaways:

• The new treatment, pasritamig, activates the body's immune system to attack prostate tumors, showing promise in early clinical trials.
• The trial enrolled patients with metastatic castration-resistant prostate cancer, a particularly aggressive form of cancer, which earlier treatments had failed to stop.
• Pasritamig works by bridging T cells to prostate cancer cells using a specially designed antibody, helping the immune system recognize and attack tumors.
• The most effective dose of pasritamig was found to be a moderate dose given as an IV infusion every six weeks, which caused minimal side effects.
• The treatment was initially intended for dose escalation, but researchers found "very encouraging signs of effectiveness--even at lower doses" (Mark Stein, MD).
• The treatment has the potential to be delivered in an outpatient setting, sparing patients frequent hospital visits and precious time away from family (Mark Stein, MD).
• The research team is now enrolling patients in a larger clinical trial to further evaluate the drug's effectiveness and safety.
• Future studies may explore using pasritamig earlier in the disease course or combining it with other treatments (Mark Stein, MD).

Statistics:

• The trial enrolled patients with metastatic castration-resistant prostate cancer.
• Pasritamig demonstration of effectiveness even at lower doses.
• Median progression-free survival of nearly eight months achieved in patients treated with pasritamig.
• 40% of patients didn't experience any side effects at all.
• Minimal side effects, including a mild fever, were experienced by patients treated with pasritamig.
• Average dosing interval of six weeks for pasritamig treatment.

Sources:

• Stein, M., et al. "Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study" (2025). Journal of Clinical Oncology. Vol 43, No. 16, June 1, 2025.
• American Society of Clinical Oncology (ASCO). (2025). 2025 ASCO Annual Meeting.